Stay updated with breaking news from Bioscience Segment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com cut shares of Grifols (NASDAQ:GRFS – Get Rating) from a buy rating to a hold rating in a research note published on Monday morning. Other analysts also recently issued research reports about the stock. AlphaValue raised shares of Grifols to a buy rating in a research report on Monday, February 6th. Barclays raised shares […]
Grifols (NASDAQ:GRFS – Get Rating) was upgraded by Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research note issued on Wednesday, The Fly reports. Several other brokerages have also recently commented on GRFS. AlphaValue upgraded Grifols to a “buy” rating in a report on Monday, February 6th. Barclays upgraded shares […]
Lapides Asset Management LLC lessened its position in shares of Grifols, S.A. (NASDAQ:GRFS – Get Rating) by 39.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 210,600 shares of the biotechnology company’s stock after selling 140,000 shares during the period. Lapides Asset Management […]
International Assets Investment Management LLC acquired a new stake in shares of Grifols, S.A. (NASDAQ:GRFS – Get Rating) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 292,567 shares of the biotechnology company’s stock, valued at approximately $5,694,000. Grifols makes up about 1.1% of International Assets Investment Management […]
Shares of Grifols, S.A. (NASDAQ:GRFS – Get Rating) have received an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective […]